E
Cytosorbents Corporation
CTSO
$1.12
-$0.01-0.89%
E
Sell
11/11/2024Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 11/11/2024 due to a decline in the solvency index, total return index and valuation index. Debt to equity increased from 0.84 to 1.1, and the quick ratio declined from 1.58 to 1.46.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 11/11/2024 due to a decline in the solvency index, total return index and valuation index. Debt to equity increased from 0.84 to 1.1, and the quick ratio declined from 1.58 to 1.46.
D
Sell
10/22/2024Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 10/22/2024 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.1172 to -$0.0763, EBIT increased 34.35% from -$4.93M to -$3.23M, and total revenue increased 1.11% from $9.79M to $9.89M.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 10/22/2024 due to a noticeable increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.1172 to -$0.0763, EBIT increased 34.35% from -$4.93M to -$3.23M, and total revenue increased 1.11% from $9.79M to $9.89M.
E
Sell
3/20/2024Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 3/20/2024 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 27.82% from -$7.17M to -$9.16M, operating cash flow declined 23.07% from -$5.21M to -$6.41M, and total revenue declined 1.62% from $8.81M to $8.67M.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 3/20/2024 due to a noticeable decline in the growth index, volatility index and total return index. EBIT declined 27.82% from -$7.17M to -$9.16M, operating cash flow declined 23.07% from -$5.21M to -$6.41M, and total revenue declined 1.62% from $8.81M to $8.67M.
D
Sell
3/1/2024Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 3/1/2024 due to an increase in the valuation index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 3/1/2024 due to an increase in the valuation index.
E
Sell
11/13/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.1398 to -$0.2072, the quick ratio declined from 1.95 to 1.21, and debt to equity increased from 0.21 to 0.28.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 11/13/2023 due to a decline in the growth index, total return index and solvency index. Earnings per share declined from -$0.1398 to -$0.2072, the quick ratio declined from 1.95 to 1.21, and debt to equity increased from 0.21 to 0.28.
D
Sell
11/3/2023Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 11/3/2023 due to an increase in the volatility index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 11/3/2023 due to an increase in the volatility index.
E
Sell
10/19/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the volatility index and total return index.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the volatility index and total return index.
D
Sell
10/4/2023Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 10/4/2023 due to an increase in the valuation index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 10/4/2023 due to an increase in the valuation index.
E
Sell
9/7/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 9/7/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.36 to 1.95, and debt to equity increased from 0.18 to 0.21.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 9/7/2023 due to a decline in the volatility index, total return index and solvency index. The quick ratio declined from 2.36 to 1.95, and debt to equity increased from 0.18 to 0.21.
D
Sell
6/5/2023Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 6/5/2023 due to an increase in the valuation index and volatility index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 6/5/2023 due to an increase in the valuation index and volatility index.
E
Sell
5/19/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 5/19/2023 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0176 to -$0.17, debt to equity increased from 0.14 to 0.18, and the quick ratio declined from 2.86 to 2.36.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 5/19/2023 due to a noticeable decline in the growth index, valuation index and solvency index. Earnings per share declined from -$0.0176 to -$0.17, debt to equity increased from 0.14 to 0.18, and the quick ratio declined from 2.86 to 2.36.
D
Sell
3/31/2023Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index, total return index and valuation index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 3/31/2023 due to an increase in the volatility index, total return index and valuation index.
E
Sell
3/16/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 3/16/2023 due to a decline in the volatility index.
D
Sell
3/14/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
3/3/2023Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D from D- on 3/3/2023 due to an increase in the volatility index, total return index and valuation index.
Cytosorbents Corporation (CTSO) was upgraded to D from D- on 3/3/2023 due to an increase in the volatility index, total return index and valuation index.
D
Sell
2/23/2023Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index, valuation index and growth index. The quick ratio declined from 3.35 to 2.72, earnings per share declined from -$0.25 to -$0.28, and EBIT declined 9.55% from -$8.23M to -$9.02M.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 2/8/2023 due to a decline in the solvency index, valuation index and growth index. The quick ratio declined from 3.35 to 2.72, earnings per share declined from -$0.25 to -$0.28, and EBIT declined 9.55% from -$8.23M to -$9.02M.
D
Sell
5/4/2022Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 5/4/2022 due to an increase in the volatility index, total return index and valuation index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 5/4/2022 due to an increase in the volatility index, total return index and valuation index.
E
Sell
4/20/2022Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 4/20/2022 due to a decline in the volatility index and total return index.
D
Sell
3/15/2022Downgrade
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 3/15/2022 due to a large decline in the total return index, solvency index and growth index. EBIT declined 76.87% from -$5.41M to -$9.56M, earnings per share declined from -$0.15 to -$0.2197, and operating cash flow declined 32.86% from -$4.13M to -$5.49M.
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 3/15/2022 due to a large decline in the total return index, solvency index and growth index. EBIT declined 76.87% from -$5.41M to -$9.56M, earnings per share declined from -$0.15 to -$0.2197, and operating cash flow declined 32.86% from -$4.13M to -$5.49M.
D
Sell
11/9/2021Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
Cytosorbents Corporation (CTSO) was upgraded to D from E+ on 11/9/2021 due to an increase in the volatility index.
E
Sell
11/8/2021Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and growth index. Operating cash flow declined 103% from -$2.04M to -$4.13M, earnings per share declined from -$0.108 to -$0.15, and total revenue declined 18.83% from $12.02M to $9.76M.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and growth index. Operating cash flow declined 103% from -$2.04M to -$4.13M, earnings per share declined from -$0.108 to -$0.15, and total revenue declined 18.83% from $12.02M to $9.76M.
D
Sell
5/1/2020Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
Cytosorbents Corporation (CTSO) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index, volatility index and solvency index.
D
Sell
3/24/2020Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 3/24/2020 due to an increase in the volatility index, valuation index and total return index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 3/24/2020 due to an increase in the volatility index, valuation index and total return index.
E
Sell
3/9/2020Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 3/9/2020 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 2.29 to 4.53, the quick ratio declined from 2.09 to 1.68, and total capital declined 14.74% from $22.92M to $19.54M.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 3/9/2020 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 2.29 to 4.53, the quick ratio declined from 2.09 to 1.68, and total capital declined 14.74% from $22.92M to $19.54M.
D
Sell
2/4/2020Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 2/4/2020 due to an increase in the volatility index.
Cytosorbents Corporation (CTSO) was upgraded to D- from E+ on 2/4/2020 due to an increase in the volatility index.
E
Sell
1/3/2020Downgrade
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 1/3/2020 due to a major decline in the total return index, volatility index and valuation index.
Cytosorbents Corporation (CTSO) was downgraded to E+ from D- on 1/3/2020 due to a major decline in the total return index, volatility index and valuation index.
D
Sell
4/3/2017Downgrade
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 4/3/2017 due to a decline in the volatility index and total return index.
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 4/3/2017 due to a decline in the volatility index and total return index.
D
Sell
3/3/2017Upgraded
Cytosorbents Corporation (CTSO) was upgraded to D from D- on 3/3/2017 due to an increase in the valuation index and volatility index.
Cytosorbents Corporation (CTSO) was upgraded to D from D- on 3/3/2017 due to an increase in the valuation index and volatility index.
D
Sell
3/11/2016Downgrade
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
Cytosorbents Corporation (CTSO) was downgraded to D- from D on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
D
Sell
11/17/2014Downgrade
Cytosorbents Corporation (CTSO) was downgraded to D from C on 11/17/2014 due to a significant decline in the efficiency index, volatility index and growth index. Net income declined 19.16% from -$1.85M to -$1.5M, earnings per share declined from -$0.0107 to -$0.0089, and total capital declined 12.18% from $9.2M to $8.08M.
Cytosorbents Corporation (CTSO) was downgraded to D from C on 11/17/2014 due to a significant decline in the efficiency index, volatility index and growth index. Net income declined 19.16% from -$1.85M to -$1.5M, earnings per share declined from -$0.0107 to -$0.0089, and total capital declined 12.18% from $9.2M to $8.08M.
C
Hold
5/23/2014Upgraded
Cytosorbents Corporation (CTSO) was upgraded to C from D on 5/23/2014 due to a significant increase in the efficiency index, volatility index and total return index. Total capital increased 312.22% from $2.63M to $10.82M, and net income increased 45.73% from -$669.1 to -$975.1.
Cytosorbents Corporation (CTSO) was upgraded to C from D on 5/23/2014 due to a significant increase in the efficiency index, volatility index and total return index. Total capital increased 312.22% from $2.63M to $10.82M, and net income increased 45.73% from -$669.1 to -$975.1.
NASDAQ
03/18/2025 9:30AM Eastern
Quotes delayed
